JCR grants Italfarmaco US, EU and Latin America rights to Hunter syndrome drug JR-141
- JCR Pharmaceuticals signed an exclusive license with Italfarmaco for JR-141 (pabinafusp alfa; Izcargo in Japan) in the US, Europe and Latin America.
- The blood-brain-barrier-penetrating enzyme replacement therapy targets Hunter syndrome (MPS II); it was launched in Japan in 2021 and is in Phase 3.
- Italfarmaco will commercialize after approvals; JCR keeps manufacturing and receives upfront, milestone, royalty and supply revenue. Amounts were not disclosed.
💡 Points
Undisclosed economics make this a structure story, not a price story. JCR hands Italfarmaco commercialization in the US, Europe and Latin America but keeps manufacturing and supply revenue, which preserves margin on a complex biologic. For Italfarmaco it is a rare-disease pipeline add; what I would want to see is Phase 3 data and regulatory timelines before judging value.
第一三共「ダトロウェイ」併用療法開発で米サミットと提携／JCRファーマ「イズカーゴ」欧米販売でライセンス契約 など｜製薬業界きょうのニュースまとめ読み（2026年10月2日） ↗